FDA approves lebrikizumab for atopic dermatitis in patients 12 years and older

News
Article

The indication is supported by trial data showing three-fourths of successfully treated patients maintained clear skin through 1 year of a lebrikizumab regimen.

FDA approves lebrikizumab for atopic dermatitis in patients 12 years and older

The US Food and Drug Administration (FDA) has approved lebrikizumab (EBGLYSS) for the treatment of patients ≥12 years old with moderate to severe atopic dermatitis who meet weight and disease severity standards warranting potential benefit from the interleukin 13 (IL-13) inhibitor therapy.1

The indication granted to Eli Lilly and Company on Friday allows for a monthly maintenance 250 mg / 2 mL injection dose of lebrikizumab, used in combination with or without topical corticosteroids, for pediatric, adolescent and adult patients who weight ≥88 lbs and have poorly controlled eczema despite prior topical prescription therapies. The company recommends lebrikizumab be administered at a staring 500 mg dose split across 2 injections at weeks 0 and 2 before shifting to a bi-weekly dose until week 16 or later when adequate clinical response is achieved.

The data supporting lebrikizumab’s indication was based on findings from the ADVocate 1 and 2 trials, as well as the ADhere trial, in which the biologic drug achieved primary outcomes including significant improvement in clear or almost clear skin per Investigators Global Assessment (IGA) scores of 0 or 1 versus placebo (38% vs 12%) among more than 1000 participants. Investigators additionally noted that 1 in 10 patients receiving lebrikizumab achieved IGA 0 or 1 by 4 weeks.

What’s more, three-fourths (77%) of patients who achieved IGA 0 or 1 at week 16 maintained their clear skin at 1 year after switching to once-monthly dosing. Another 48% of patients who achieved IGA 0 or 1 at week 16 who switched from lebrikizumab to placebo maintained their clear skin at 1 year.

In a statement accompanying the approval, Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at George Washington University School of Medicine and Health Sciences, said access to lebrikizumab provides a wide array of patients “a new first-line biologic treatment option for moderate-to-severe disease when topical prescriptions aren't enough."

"Patients still struggle to control their moderate-to-severe atopic dermatitis with currently available therapies,” Silverberg said. “Many experience poor long-term disease control, and severe itch can significantly impact their daily lives.”

The new indication comes after a previous stall in the pipeline delivery for Eli Lilly, as their application for lebrikizumab for the indicated eczema population previously received a Complete Response Letter (CRL) before resubmission this April.2

References

  1. PR Newswire. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. Press release. Published September 13, 2024. Accessed September 13, 2024. https://prnmedia.prnewswire.com/news-releases/fda-approves-lillys-ebglyss-lebrikizumab-lbkz-for-adults-and-children-12-years-and-older-with-moderate-to-severe-atopic-dermatitis-302248062.html
  2. Fitch J. BLA resubmitted for lebrikizumab to treat AD patients 12 years and up. Contemporary Pediatrics. Published April 30, 2024. https://www.contemporarypediatrics.com/view/bla-resubmitted-for-lebrikizumab-to-treat-ad-patients-12-years-and-up

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Wendy Ripple, MD
Wendy Ripple, MD
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
Related Content
© 2025 MJH Life Sciences

All rights reserved.